000 02341 a2200709 4500
005 20250516153028.0
264 0 _c20140610
008 201406s 0 0 eng d
022 _a1476-5594
024 7 _a10.1038/onc.2013.169
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aGang, E J
245 0 0 _aSmall-molecule inhibition of CBP/catenin interactions eliminates drug-resistant clones in acute lymphoblastic leukemia.
_h[electronic resource]
260 _bOncogene
_cApr 2014
300 _a2169-78 p.
_bdigital
500 _aPublication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
650 0 4 _aAnimals
650 0 4 _aAntineoplastic Agents
_xpharmacology
650 0 4 _aAsparaginase
_xpharmacology
650 0 4 _aBridged Bicyclo Compounds, Heterocyclic
_xpharmacology
650 0 4 _aCell Line, Tumor
650 0 4 _aCell Proliferation
_xdrug effects
650 0 4 _aCell Survival
_xdrug effects
650 0 4 _aDexamethasone
_xpharmacology
650 0 4 _aDown-Regulation
_xdrug effects
650 0 4 _aDrug Resistance, Neoplasm
650 0 4 _aDrug Synergism
650 0 4 _aHumans
650 0 4 _aInhibitor of Apoptosis Proteins
_xgenetics
650 0 4 _aMice
650 0 4 _aMice, Inbred NOD
650 0 4 _aMice, SCID
650 0 4 _aMutation
650 0 4 _aPeptide Fragments
_xantagonists & inhibitors
650 0 4 _aPrecursor Cell Lymphoblastic Leukemia-Lymphoma
_xdrug therapy
650 0 4 _aPyrimidinones
_xpharmacology
650 0 4 _aSialoglycoproteins
_xantagonists & inhibitors
650 0 4 _aSurvivin
650 0 4 _aVincristine
_xpharmacology
650 0 4 _aWnt Signaling Pathway
650 0 4 _aXenograft Model Antitumor Assays
650 0 4 _abeta Catenin
_xmetabolism
700 1 _aHsieh, Y-T
700 1 _aPham, J
700 1 _aZhao, Y
700 1 _aNguyen, C
700 1 _aHuantes, S
700 1 _aPark, E
700 1 _aNaing, K
700 1 _aKlemm, L
700 1 _aSwaminathan, S
700 1 _aConway, E M
700 1 _aPelus, L M
700 1 _aCrispino, J
700 1 _aMullighan, C G
700 1 _aMcMillan, M
700 1 _aMüschen, M
700 1 _aKahn, M
700 1 _aKim, Y-M
773 0 _tOncogene
_gvol. 33
_gno. 17
_gp. 2169-78
856 4 0 _uhttps://doi.org/10.1038/onc.2013.169
_zAvailable from publisher's website
999 _c22800189
_d22800189